Publication | Closed Access

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

Phase Ii TrialMalignant DiseaseOpen-label Single-armMedicinePathologyImmune Checkpoint InhibitorHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation OncologyMolecular Oncology